EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Postmarketing surveillance of nivolumab plus ipilimumab combination therapy in Japanese patients with unresectable malignant melanoma

Naoya Yamazaki iD, Yoshio Kiyohara, Hisashi Uhara iD, Tetsuya Tsuchida iD, Ai Yoshida, Takako Yamada, Akira Komoto

The Journal of Dermatology · 2023

DOI: 10.1111/1346-8138.16820 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Dermatology, 2023. Verfasst von Naoya Yamazaki und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Ipilimumab, Melanoma, Nivolumab. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bristol-Myers Squibb, Ono Pharmaceutical.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although malignant melanoma is relatively rare in Japan, it is often diagnosed at a later stage than in Western countries. Nivolumab and ipilimumab are immune checkpoint inhibitors targeting programmed death 1 and cytotoxic T‐lymphocyte‐associated protein 4, respectively. Owing to their complementary anticancer effects, nivolumab and ipilimumab combination therapy (N + I) has been studied and approved for treating malignant melanoma in various countries including Japan. Real‐world postmarketing surveillance was implemented to record treatment‐related adverse events (TRAEs) in patients treated with N + I following its approval in Japan. Patients were eligible for registration if they had unresectable malignant melanoma and started N + I between September 2018 and August 2019. The observation period was 13 weeks from starting N + I. Only safety information was collected and evaluated. The final case report form lock was March 2021. Overall, 173 patients (median age, 66.0 years; performance status 0–1, 88.4%; skin: 53.2%; mucosal: 32.4%) were eligible for the analyses. Overall, 34.1% of patients completed 4 doses of N + I. N + I was discontinued by 63.0% (due to adverse events in 67.9% and disease progression/death in 22.9%). Any grade and grade ≥3 TRAEs were reported in 73.41% and 52.02%, respectively. TRAEs in ≥10 patients were hepatic function abnormal (any grade/grade ≥3: 23.12%/13.29%), pyrexia (10.40%/0.58%), diarrhea (9.25%/2.89%), rash (8.67%/0.58%), hypophysitis (5.78%/5.20%), interstitial lung disease (5.78%/2.89%), and liver disorder (5.78%/4.62%). TRAEs were classified as recovered (36.99% of patients), recovering (44.51%), unrecovered (13.29%), recovered with sequelae (2.31%), and death (1.73%). Overall, 24 of 34 patients (70.59%) with gastrointestinal‐related and 53 of 65 (81.54%) liver‐related TRAEs received treatment, such as a steroid with/without an immunosuppressant; most patients recovered within 1 to 2 months. In conclusion, this postmarketing surveillance of N + I in patients with unresectable malignant melanoma revealed no new safety concerns compared with results of prior studies. Immune‐related TRAEs were generally manageable by appropriate treatment including a steroid.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsIpilimumabMelanomaNivolumabSkin NeoplasmsAgedHumansDisease ProgressionEast Asian PeopleProduct Surveillance, PostmarketingCutaneous Malignant Melanoma

Stichwörter der Autor:innen

combination therapyipilimumabmalignant melanomanivolumabpostmarketing surveillance

Substanzen

IpilimumabNivolumab

Autor:innen und Institutionen

  • Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Dermatology Division, Shizuoka Cancer Center Hospital, Shizuoka, Japan.
  • Department of Dermatology, Sapporo Medical University School of Medicine, Sapporo, Japan.
  • Department of Dermatology, Saitama Medical University, Saitama, Japan.
  • Patient Safety Japan, Bristol-Myers Squibb K.K., Tokyo, Japan.

ORCID-Profile: Naoya Yamazaki, Hisashi Uhara, Tetsuya Tsuchida

Förderung

  • Bristol-Myers Squibb
  • Ono Pharmaceutical

Zitieren

APA

Yamazaki, N., Kiyohara, Y., Uhara, H., Tsuchida, T., Yoshida, A., Yamada, T., & Komoto, A. (2023). Postmarketing surveillance of nivolumab plus ipilimumab combination therapy in Japanese patients with unresectable malignant melanoma. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.16820

Vancouver

Yamazaki N, Kiyohara Y, Uhara H, Tsuchida T, Yoshida A, Yamada T, et al. Postmarketing surveillance of nivolumab plus ipilimumab combination therapy in Japanese patients with unresectable malignant melanoma. The Journal of Dermatology. 2023. doi:10.1111/1346-8138.16820

BibTeX
@article{Yamazaki2023,
  author = {Yamazaki, Naoya and Kiyohara, Yoshio and Uhara, Hisashi and Tsuchida, Tetsuya and Yoshida, Ai and Yamada, Takako and Komoto, Akira},
  title = {Postmarketing surveillance of nivolumab plus ipilimumab combination therapy in Japanese patients with unresectable malignant melanoma},
  journal = {The Journal of Dermatology},
  year = {2023},
  doi = {10.1111/1346-8138.16820}
}
Kostenlos starten →